Table 2.
|
|
CRBLM |
CRBLM |
CRBLM |
FCTX |
FCTX |
PONS |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
vs |
vs |
vs |
vs |
vs |
vs |
||||||
|
|
FCTX |
PONS |
TCTX |
PONS |
TCTX |
TCTX |
||||||
KEGG pathways | R | N | R | N | R | N | R | N | R | N | R | N | |
1 |
TGF- β signaling pathway |
○ |
○ |
○ |
○ |
|
|
|
○ |
|
|
○ |
|
2 |
Glioma ∗ |
○ |
○ |
○ |
○ |
○ |
|
|
○ |
|
|
|
|
3 |
MAPK signaling pathway |
○ |
○ |
○ |
○ |
|
|
|
|
|
○ |
|
|
4 |
Axon guidance ∗ |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
5 |
Phosphatidylinositol signaling system |
○ |
○ |
|
○ |
|
|
|
|
|
|
|
|
6 |
mTOR signaling pathway |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
|
7 |
Adipocytokine signaling pathway |
○ |
○ |
|
○ |
|
○ |
|
|
|
|
|
|
8 |
Pancreatic cancer |
○ |
○ |
|
○ |
|
|
|
○ |
|
|
|
|
9 |
Endocytosis |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
○ |
|
10 |
Focal adhesion |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
○ |
|
11 |
Insulin signaling pathway |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
12 |
Neurotrophin signaling pathway ∗ |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
13 |
Colorectal cancer |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
14 |
Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
○ |
○ |
○ |
○ |
|
|
|
|
|
○ |
|
|
15 |
Wnt signaling pathway |
○ |
○ |
○ |
○ |
|
○ |
|
|
|
○ |
|
|
16 |
Non-small cell lung cancer |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
17 |
Adherens junction |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
○ |
|
18 |
ErbB signaling pathway |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
19 |
Pathways in cancer |
○ |
○ |
○ |
○ |
|
|
|
○ |
|
|
○ |
|
20 |
Glycosaminoglycan biosynthesis - heparan sulfate |
○ |
○ |
○ |
○ |
|
|
|
○ |
○ |
|
|
|
21 |
Type II diabetes mellitus |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
22 |
Melanoma |
○ |
○ |
|
○ |
|
|
|
○ |
|
|
|
|
23 |
Renal cell carcinoma |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
24 |
Inositol phosphate metabolism |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
25 |
Chronic myeloid leukemia |
○ |
○ |
○ |
○ |
|
|
|
○ |
|
|
|
|
26 |
T cell receptor signaling pathway |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
27 |
Small cell lung cancer |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
|
28 |
Fc gamma R-mediated phagocytosis |
○ |
○ |
|
○ |
|
|
|
|
|
|
|
|
29 |
Prostate cancer |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
|
30 |
Salivary secretion |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
31 |
Osteoclast differentiation |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
32 |
Regulation of actin cytoskeleton |
○ |
○ |
○ |
○ |
|
|
|
|
|
|
|
|
33 |
Endocrine and other factor-regulated calcium reabsorption |
○ |
○ |
|
|
|
|
|
|
|
|
|
|
34 |
Lysine degradation |
|
|
○ |
○ |
|
○ |
|
|
|
|
|
|
35 |
Circadian rhythm - mammal |
|
|
○ |
○ |
|
|
|
○ |
|
○ |
|
|
36 |
Glycosaminoglycan biosynthesis - chondroitin sulfate |
|
|
○ |
○ |
|
|
|
|
○ |
|
|
|
37 |
N-Glycan biosynthesis |
|
|
○ |
○ |
|
|
|
|
|
|
|
|
38 |
Long-term depression |
|
|
|
○ |
|
|
|
○ |
|
|
|
|
39 |
Prion diseases |
|
|
|
○ |
|
|
|
|
|
|
○ |
|
40 |
ECM-receptor interaction |
|
|
○ |
|
|
|
|
|
○ |
|
|
|
41 |
Tight junction |
|
|
|
○ |
|
|
|
|
|
○ |
|
|
42 |
Hypertrophic cardiomyopathy (HCM) |
|
|
|
○ |
|
|
|
|
|
○ |
|
|
43 |
Cell adhesion molecules (CAMs) |
|
|
|
|
|
○ |
○ |
|
|
|
|
|
44 |
Dilated cardiomyopathy |
|
|
|
○ |
|
|
|
|
|
○ |
|
|
45 |
Fatty acid biosynthesis |
○ |
|
|
|
|
|
|
|
|
|
|
|
46 |
Long-term potentation |
|
|
○ |
|
|
|
|
|
|
|
|
|
47 |
Ubiquitin mediated proteolysis |
|
|
○ |
|
|
|
|
|
|
|
|
|
48 |
Thyroid cancer |
|
|
○ |
|
|
|
|
|
|
|
|
|
49 |
Notch signaling pathway |
|
|
○ |
|
|
|
|
|
|
|
|
|
50 |
Mismatch repair |
|
|
○ |
|
|
|
|
|
|
|
|
|
51 |
Acute myeloid leukemia |
|
|
○ |
|
|
|
|
|
|
|
|
|
52 |
Glycosphingolipid biosynthesis - lacto and neolacto series |
|
|
○ |
|
|
|
|
|
|
|
|
|
53 |
Glycosaminoglycan biosynthesis - keratan sulfate |
|
|
|
○ |
|
|
|
|
|
|
|
|
54 |
Biotin metabolism |
|
|
|
○ |
|
|
|
|
|
|
|
|
55 |
Gap junction |
|
|
|
○ |
|
|
|
|
|
|
|
|
56 |
Gastric acid secretion |
|
|
|
○ |
|
|
|
|
|
|
|
|
57 |
Taurine and hypotaurine metabolism |
|
|
|
○ |
|
|
|
|
|
|
|
|
58 |
Aldosterone-regulated sodium reabsorption |
|
|
|
○ |
|
|
|
|
|
|
|
|
59 |
GnRH signaling pathway |
|
|
|
○ |
|
|
|
|
|
|
|
|
60 |
Metabolism of xenobiotics by cytochrome P450 |
|
|
|
|
|
○ |
|
|
|
|
|
|
61 |
Mucin type O-Glycan biosynthesis |
|
|
|
|
|
|
|
○ |
|
|
|
|
62 |
Biosynthesis of unsaturated fatty acids |
|
|
|
|
|
|
|
|
○ |
|
|
|
63 |
Viral myocarditis |
|
|
|
|
|
|
|
|
|
○ |
|
|
64 |
Cytokine-cytokine receptor interaction |
|
|
|
|
|
|
|
|
|
|
○ |
|
65 |
Hematopoietic cell lineage |
|
|
|
|
|
|
|
|
|
|
○ |
|
66 | Valine, leucine and isoleucine biosynthesis | ○ |
KEGG pathways marked with ○ are enriched by target genes of miRNAs selected in Table 1. “R” and “N” indicate whether the relationship between miRNA expression and target gene mRNA is reciprocal (nonreciprocal). Pathways asterisked and bold faced are directly related to brain and neurons, respectively, and discussed in detail in the Supplementary Document (see Additional file 1).